FiercePharma3d
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
STAT13d
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
New York Post23d
Ozempic 3.0? This drug causes the greatest weight loss — by far
Tirzepatide, a weekly GLP-1 and GIP drug sold under the brand name Zepbound, produced weight loss of up to 17.8% after 72 weeks, the analysis found. REUTERS McGill researchers are calling for more ...
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Benzinga.com19d
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is an injectable prescription medication ... The medication also promotes weight loss, with patients losing an average of 45 pounds or 18% of their body weight, during the trials.
San Diego Union-Tribune1mon
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...
WFLA News Channel 822d
Wegovy to Zepbound: The Pros and Cons of Weight Loss Medications
Wegovy: FDA-approved for the management of obesity in June 2021, this medication has gained widespread attention for its effectiveness in supporting weight loss. Zepbound: Recently FDA-approved in ...